Innovation1 Biotech Inc.
company.status.inactiveCIK 1629205fmd_0QH030SJ5R3GG6P6XR490RAZDEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Sep 01, 2014 to Feb 29, 2024, 38 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Net interest income | – | – | – | – | – | 0 | 0 | 0 | – |
| Gross profit | – | – | – | (0) | (0) | (0) | 0 | 0 | 0 |
| Realized investment gains (losses) | – | – | – | – | – | – | (0) | 0 | – |
| Research and development | – | – | – | – | – | – | 0 | 0 | 0 |
| Total operating expenses | (0) | 0 | 0 | 0 | 1 | 0 | 0 | 5 | 1 |
| Operating income | – | – | – | (0) | (1) | (0) | (0) | (5) | (1) |
| Interest expense | – | – | – | 0 | 0 | 1 | 0 | 0 | 0 |
| Interest and investment income | – | – | – | – | 0 | 0 | 0 | – | – |
| Other non-operating income (expense) | – | – | – | 1 | (0) | 2 | (1) | 36 | 5 |
| Net income | (0) | (0) | (0) | (1) | (0) | (3) | 1 | (41) | (6) |
| Net income to common shareholders | – | – | – | – | – | – | 1 | (42) | (14) |